Generic placeholder image

Current Analytical Chemistry

Author(s): Vidhya K. Bhusari*, Minal R. Ghante, Akanksha Lonkar, Preeti D. Kulkarni and Supriya G. Jagtap

DOI: 10.2174/1573411019666230605111507

DownloadDownload PDF Flyer Cite As
LC-UV and LC-MS Characterization of Stress Degradation Behavior of Levocetirizine Using a Green Mobile Phase

Page: [391 - 402] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Introduction: The current investigation's objective was to develop an HPLC method along with a validated stability-indicating method and analyzing the behavior of levocetirizine degradation under various ICH-suggested stress conditions using LC-UV and LC-MS with a triple quadrupole mass analyzer.

Methods: Levocetirizine was exposed to various stressors while performing degradation studies. Using LC-UV and LC-MS methods, the degradation products formed in different stress environments were studied. The drug and degradation products were successfully separated using a Thermo Hypersil BDSC18 column having a dimension of 250 mm length, 4.6 mm internal diameter, and a particle size of 5.0 μm. The isocratic green mobile phase contained methanol:water in the proportion of 65:35 at a flow rate of 1 mL/min, and the selected wavelength for the UV detector was 230 nm.

Results: Significant degradation was found in acidic, alkaline, and oxidative conditions, whereas in photo and neutral conditions, no degradation products were formed. The drug was fairly stable in the solid state.

Conclusion: The values of m/z obtained from LC-MS after exposing the drug to different stress conditions were used to study fragmentation patterns, characterize the structure of the degradation product, and design the degradation pathway.

Graphical Abstract

[1]
ICH Q1A(R2), Stability Testing of New Drug Substances and Products. 2003. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
[2]
ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology. 2005. Available from: https://www.gmp-compliance.org/guidelines/gmp-guideline/ich-q2r1-validation-of-analytical-procedures-text-and-methodology
[3]
Day, J.H.; Ellis, A.K.; Rafeiro, E. Levocetirizine: A new selective H1 receptor antagonist for use in allergic disorders. Med. Actual., 2004, 40(5), 415-421.
[http://dx.doi.org/10.1358/dot.2004.40.5.850489] [PMID: 15319796]
[4]
Dhaneshwar, S.R.; Bhutale, K.; Mhaske, V.; Kadam, S. Stability indicating HPLC method for the determination of levocetirizine dihydro-chloride as bulk and in pharmaceutical dosage forms. J. Pharm. Pharmacol., 2006, 58, 1-5.
[5]
Akula, V.K.; Sinha, B.N. seok, H.J. Stability indicating HPLC method using core shell stationary phase for the determination of related substances in levocetirizine dihydrochloride oral solution. Indian J. Pharm. Educ. Res., 2017, 51(4s), s769-s775.
[http://dx.doi.org/10.5530/ijper.51.4s.111]
[6]
AlAani, H.; Alashkar, I. Development and validation of stability indicating RP-HPLC method for the analysis of levocetirizine dihydro-chloride and fexofenadine hydrochloride in the presence of parabens in liquid dosage forms. Int. J. Pharm. Sci. Res., 2013, 23(2), 64-71.
[7]
Hommoss, R.; Elzein, H.; Haidar, S. Determination of levocetirizine configurational stability in tablets using chiral HPLC method. Int. J. Pharm. Pharm. Sci., 2011, 3(2), 103-107.
[8]
Basu, A.; Basak, K.; Chakraborty, M.; Rawat, I.S. Simultaneous RP-HPLC estimation of levocetirizine hydrochloride and montelukast sodium in tablet dosage form. Int. J. Pharm. Tech. Res., 2011, 3, 405-410.
[9]
Ramalingam, S.; Manavalam, R.; Valliappan, K. HPLC method for the simultaneous determination of Levocetirizine, Ambroxol and Montelukast in human plasma employing response surface methodology. Int. J. Drug Dev Res., 2012, 4(3), 173-185.
[10]
Suryan, A.L.; Bhusari, V.K.; Rasal, K.S.; Dhaneshwar, S.R. Simultaneous quantitation and validation of paracetamol, phenylpropanola-mine hydrochloride and cetirizine hydrochloride by RP-HPLC in bulk drug and formulation. Int. J. Pharm. Sci. Drug Res., 2011, 3(4), 303-308.
[11]
Dhaneshwar, S.R.; Bhusari, V.K. Development of a validated stability-indicating UPLC assays method for Levocetirizine. J. Anal. Bioanal. Tech., 2011, 2(6), 69-72.
[12]
Bhusari, V.K.; Dhaneshwar, S.R. Application of a stability-indicating TLC method for the quantitative determination of Levocetirizine in pharmaceutical dosage forms. Int. J. Adv. Pharm. Sci., 2010, 1, 387-394.
[13]
Rashed, N.S.; Nasr, Z.A. Simultaneous determination of levocetirizine dihydrochloride and montelukast sodium in human plasma by LC-MS/MS: Development, validation, and application to a human pharmacokinetic study. Acta Chromatogr., 2019, 31(3), 194-200.
[http://dx.doi.org/10.1556/1326.2018.00439]
[14]
Khatri, S. Bioanalytical method development and validation for the estimation of Levocetirizine in blood plasma by using RP-HPLC. J. Drug Deliv. Ther., 2018, 8(5-s), 288-292.
[http://dx.doi.org/10.22270/jddt.v8i5-s.1977]
[15]
Jain, N.; Jain, D.; Jain, R.; Patel, V.; Patel, P.; Jain, S. Bioanalytical method development and validation for the determination of levocetirizine in pharmaceutical dosage form and human plasma by RP-HPLC. J. Appl. Pharm. Sci., 2016, 6(10), 063-067.
[http://dx.doi.org/10.7324/JAPS.2016.601008]